Esophageal cancer is the sixth leading causes of cancer mortality worldwide (1). In North
America, adenocarcinoma has become the most common histology whereas squamous …

This chapter presents a series of questions and answers on controversies, consensus, and
new targets of metastatic esophagogastric cancer. It commences with a discourse on optimal …

Esophageal adenocarcinoma (EAC) affects approximately 17,000 individuals per year in the
United States, is increasing in incidence, and is associated with an exceptionally high …

As one-half of patients with esophagogastric cancer (EGC) present with metastatic disease
and the majority of patients with locally advanced disease will eventually develop metastatic …

This timely issue of Hematology/Oncology Clinics of North America highlights the current
management of cancers of the foregut (esophagus and stomach). Cancers of the esophagus …

Although combination chemotherapy has been shown to be more effective than single
agents in advanced esophagogastric cancer, the better response rates have not fulfilled …

GASTRIC AND ESOPHAGEAL cancers, although rel-atively uncommon diseases in western
countries, account for substantial cancer-related morbidity and mortality worldwide. Despite …

Because of the poor prognosis for patients with locally advanced and metastatic
esophageal, gastroesophageal junction and gastric cancers, increasing attention has …

Due to its increasing incidence and low survival rate, esophageal cancer (EC) is now
considered, even by non-medical professionals, as an extremely difficult cancer to beat akin …

The continuing high incidence of oesophago-gastric cancer in Eastern countries along with
the rising incidence, particularly of adenocarcinomas, in Western countries has led these …